• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Dova Pharmaceuticals

Quote




" Mercy bonuses" need to be paid or the sales force will slowly start to leave.. This happens in the 1st year with most start-ups due to non-existent coverage and a poor distribution model. Mgmt is prepared for this. Is it true that there are several territories that have yet to get 1 Rx?
 




anonymous said:
" Mercy bonuses" need to be paid or the sales force will slowly start to leave.. This happens in the 1st year with most start-ups due to non-existent coverage and a poor distribution model. Mgmt is prepared for this. Is it true that there are several territories that have yet to get 1 Rx?
Click to expand...

Yes and many with 1-3 after 4 months
 




anonymous said:
Yes and many with 1-3 after 4 months
Click to expand...
Welp...don’t say we didn’t tell you so! If Dova had put anyone into leadership with actual rare disease and start-up experience, and not just big pharma, they would have projected Y1 differently. In rare disease there is typically a 4-6 month ramp up period to educate HCPs, get buy-in, identify patients, and then for THIS particular product you have the additional wait period until till the patient’s first procedure to need the script. I would have projected 6-9 months for things to get rolling and used MBOs for bonus. But then again, what do I know...I’ve only done this rare disease song and dance 3-4 times.
 




anonymous said:
Welp...don’t say we didn’t tell you so! If Dova had put anyone into leadership with actual rare disease and start-up experience, and not just big pharma, they would have projected Y1 differently. In rare disease there is typically a 4-6 month ramp up period to educate HCPs, get buy-in, identify patients, and then for THIS particular product you have the additional wait period until till the patient’s first procedure to need the script. I would have projected 6-9 months for things to get rolling and used MBOs for bonus. But then again, what do I know...I’ve only done this rare disease song and dance 3-4 times.
Click to expand...

Managers are clueless. Reach and frequency is their strategy. I guess it’s BMS way
 




















What does everyone think about Mulpleta's lower WAC price ($8,500 vs. $9,000-$13,500)? Obviously not going to help things, especially in places where we are trying to secure access.
 




anonymous said:
What does everyone think about Mulpleta's lower WAC price ($8,500 vs. $9,000-$13,500)? Obviously not going to help things, especially in places where we are trying to secure access.
Click to expand...
Acquisition costs may be lower but the cost to uae their drug va ours makes up the difference, in my mind. Not to mention the fact of increased PVTs for their product. No brainer!
 




Major concerns that Dova is manipulating investors by implying sales have occurred by reporting the number of “future sales” (aka enrollments) to wall street. Sales management is pushing sales team to get commitments or forms completed for “future” cases and many are being rewarded financially without shipped product. In addition, sale managements is pushing for refills on all cases; even when refills are not appropriate for the patient or provider. Again, this inflates the number of “prescriptions” for reporting. In addition, sales management is highly suggesting avoiding discussion of the clinical trial platelet count threshold of 50000 to encourage prescribing in patient platelet count above 50000, which was not studied.
 
















anonymous said:
Major concerns that Dova is manipulating investors by implying sales have occurred by reporting the number of “future sales” (aka enrollments) to wall street. Sales management is pushing sales team to get commitments or forms completed for “future” cases and many are being rewarded financially without shipped product. In addition, sale managements is pushing for refills on all cases; even when refills are not appropriate for the patient or provider. Again, this inflates the number of “prescriptions” for reporting. In addition, sales management is highly suggesting avoiding discussion of the clinical trial platelet count threshold of 50000 to encourage prescribing in patient platelet count above 50000, which was not studied.
Click to expand...
 












anonymous said:
Great. We now work in a pod! Expansion reps get credit for our business. Time to ramp up the resume. I didn’t sign up for this BS.
Click to expand...


And most were just called and asked if they wanted to Come work for the company...no interview at all. I know of 8 people from my company that were brought over this way...that’s a bit crazy within itself. And now they are starting to see there’s no clear direction. When you are told one day ..”nope you do not call on GIs “ and the next day you find out they are now doing a co-promote with another company...something is not right...flying by the seat of their pants it appears.
 




anonymous said:
And most were just called and asked if they wanted to Come work for the company...no interview at all. I know of 8 people from my company that were brought over this way...that’s a bit crazy within itself. And now they are starting to see there’s no clear direction. When you are told one day ..”nope you do not call on GIs “ and the next day you find out they are now doing a co-promote with another company...something is not right...flying by the seat of their pants it appears.
Click to expand...


What do you expect? The guy leading the sales force is from GSK and has ZERO small pharma start up experience. You get what you pay for...
 




Top Bottom
Back
Quote